

S2 Table. Incidence of serious TEAEs and ADRs with clofarabine use (n=60)

	Incidence of serious TEAEs	Incidence of serious ADRs
No. of patients	37 (61.7) [89]	21 (35.0) [49]
Febrile neutropenia	17 (28.3) [24]	16 (26.7) [19]
Sepsis	8 (13.3) [9]	4 (6.7) [5]
Septic shock	5 (8.3) [5]	1 (1.7) [1]
Cytomegalovirus infection	4 (6.7) [4]	1 (1.7) [1]
Pneumonia	4 (6.7) [4]	2 (3.3) [2]
Infection	3 (5.0) [3]	-
Lung infection	3 (5.0) [3]	1 (1.7) [1]
Herpes zoster	2 (3.3) [3]	-
Cystitis	2 (3.3) [2]	-
Device related infection	2 (3.3) [2]	2 (3.3) [2]
Parainfluenzae virus infection	2 (3.3) [2]	2 (3.3) [2]
Pneumonia fungal	2 (3.3) [2]	-
Pancreatitis	2 (3.3) [2]	2 (3.3) [2]
Hepatitis	2 (3.3) [2]	2 (3.3) [2]
Atypical pneumonia	1 (1.7) [2]	-
BK virus infection	1 (1.7) [1]	1 (1.7) [1]
Bacterial sepsis	1 (1.7) [1]	1 (1.7) [1]
Escherichia sepsis	1 (1.7) [1]	-
Fungal infection	1 (1.7) [1]	1 (1.7) [1]
Herpes simplex sepsis	1 (1.7) [1]	-
Mycoplasma infection	1 (1.7) [1]	1 (1.7) [1]
Pneumonia respiratory syncytial	1 (1.7) [1]	-
viral		
Pseudomonal sepsis	1 (1.7) [1]	-
Ascites	1 (1.7) [1]	1 (1.7) [1]
Acute kidney injury	1 (1.7) [1]	-
Cystitis hemorrhagic	1 (1.7) [1]	1 (1.7) [1]
Acute respiratory distress syndrome	1 (1.7) [1]	-
Pleural effusion	1 (1.7) [1]	1 (1.7) [1]

Alanine aminotransferase increased	1 (1.7) [1]	1 (1.7) [1]
Amylase increased	1 (1.7) [1]	1 (1.7) [1]
Aspartate aminotransferase increased	1 (1.7) [1]	1 (1.7) [1]
Lipase increased	1 (1.7) [1]	1 (1.7) [1]
Pyrexia	1 (1.7) [1]	1 (1.7) [1]
Leukaemic infiltration hepatic	1 (1.7) [1]	-
Cerebral infarction	1 (1.7) [1]	-

MedDRA ver. 20.1. Note: Denominator of percentage is the number of patients. Adverse events are displayed as 'number of patients (percentage of patients) [number of events]'. ADRs, adverse drug reactions; n, total patients analyzed; TEAEs, treatment-emergent adverse events.